Neoadjuvant Pazopanib Treatment in High-Risk Soft Tissue Sarcoma: A Quantitative Dynamic 18F-FDG PET/CT Study of the German Interdisciplinary Sarcoma Group
| العنوان: | Neoadjuvant Pazopanib Treatment in High-Risk Soft Tissue Sarcoma: A Quantitative Dynamic 18F-FDG PET/CT Study of the German Interdisciplinary Sarcoma Group |
|---|---|
| المؤلفون: | Timo Gaiser, Matthias Schwarzbach, Hans-Günter Derigs, Antonia Dimitrakopoulou-Strauss, Ulrike I. Attenberger, Ulrich Ronellenfitsch, Ioannis Karampinis, Bernd Kasper, Jens Jakob, Kai Nowak, Christos Sachpekidis, Lothar R. Pilz, Peter Hohenberger |
| المصدر: | Cancers Volume 11 Issue 6 Cancers, Vol 11, Iss 6, p 790 (2019) |
| بيانات النشر: | Multidisciplinary Digital Publishing Institute, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Population, Standardized uptake value, lcsh:RC254-282, 030218 nuclear medicine & medical imaging, SUV, dynamic 18F-FDG PET/CT, pazopanib, soft tissue sarcoma (STS), two-tissue compartment model, Pazopanib, 03 medical and health sciences, 0302 clinical medicine, medicine, ddc:610, Radical surgery, education, Neoadjuvant therapy, education.field_of_study, medicine.diagnostic_test, business.industry, Soft tissue sarcoma, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 3. Good health, Oncology, Positron emission tomography, 030220 oncology & carcinogenesis, Sarcoma, Radiology, business, medicine.drug |
| الوصف: | The outcome of high-risk soft tissue sarcoma (STS) is poor with radical surgery being the only potentially curative modality. Pazopanib is a multikinase inhibitor approved for the treatment of metastatic STS. Herein, in terms of the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS) trial, we evaluate the potential role of kinetic analysis of fludeoxyglucose F-18 (18F-FDG) data derived from the application of dynamic positron emission tomography/computed tomography (PET/CT) in response assessment to pazopanib of STS patients scheduled for surgical resection. Sixteen STS patients treated with pazopanib as neoadjuvant therapy before surgery were enrolled in the analysis. All patients underwent dynamic PET/CT prior to and after pazopanib treatment. Data analysis consisted of visual (qualitative) analysis of the PET/CT scans, semi-quantitative evaluation based on standardized uptake value (SUV) calculations, and quantitative analysis of the dynamic 18F-FDG PET data, based on two-tissue compartment modeling. Resection specimens were histopathologically assessed and the percentage of regression grade was recorded in 14/16 patients. Time to tumor relapse/progression was also calculated. In the follow-up, 12/16 patients (75%) were alive without relapse, while four patients (25%) relapsed, among them one patient died. Median histopathological regression was 20% (mean 26%, range 5&ndash 70%). The studied population was dichotomized using a histopathological regression grade of 20% as cut-off. Based on this threshold, 10/14 patients (71%) showed partial remission (PR), while stable disease (SD) was seen in the rest 4 evaluable patients (29%). Semi-quantitative evaluation showed no statistically significant change in the widely used PET parameters, SUVaverage and SUVmax. On the other hand, 18F-FDG kinetic analysis revealed a significant decrease in the perfusion-related parameter K1, which reflects the carrier-mediated transport of 18F-FDG from plasma to tumor. This decrease can be considered as a marker in response to pazopanib in STS and could be due to the anti-angiogenic effect of the therapeutic agent. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2072-6694 |
| DOI: | 10.3390/cancers11060790 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c041b54d3c9134a7e384da84c3da4a4Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....2c041b54d3c9134a7e384da84c3da4a4 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20726694 |
|---|---|
| DOI: | 10.3390/cancers11060790 |